Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $33
Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $28 to $33.